Singapore, July 6 -- Matica Biotechnology has entered a partnership with VaxDome to support development of antigen-agnostic antiviral-vaccine hybrid candidates.

Under the agreement, Matica Bio will provide process development, analytical development and production of non-GMP and cGMP clinical materials. The work will be carried out at Matica Bio's purpose-built facility in College Station, Texas.

This is relevant because vaccine development is increasingly being shaped by the need for flexible platforms that can respond to fast-changing viral threats. Traditional vaccine development often depends on identifying, characterising and updating antigens against specific viral strains. Antigen-agnostic approaches aim to provide broader protec...